IMARA Inc. (IMRA) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual events or results could differ materially from those expressed or implied by these forward-looking statements as a result of various important factors, including those set forth in the risk factors section of our most recent quarterly report on Form 10-Q, that we filed with the SEC this morning, as well as any other filings that we may make with the SEC. Any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. With that, I'll now turn the call over to Amara's President and CEO, Rahul Blal, who will provide an overview of our third quarter and key recent accomplishments. I'll then return following Rahul's discussion to review our third quarter financial results, and we'll then open the call for any questions. Rahul? Thank you, Mike. Good morning, everyone, and thank you for joining today's call. The third quarter and recent weeks have been productive periods for AMARA, and specifically on IMR687, which we'll also refer to in its generic name, to Vinotrin. We are pleased to have made substantial progress in our ongoing Phase IIb trials, and we expect to report interim data from both our ARTID trial in sickle cell disease and FORTE trial in beta-valcemia this quarter. Furthermore, we have t...